COMP <GO>
CBT vs FCX // RSI-14 & 200D SMA MOMENTUM
Cabot Corporation (NYSE) VS. Freeport-McMoRan Inc. (NYSE) • 15-METRIC TALLY: CBT 6
— FCX 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: FCX
LAST: $74.43 (+0.79%) • MKT CAP: $3.81B
rsi-technicals
40.6
LAST: $62.47 (-5.55%) • MKT CAP: $94.98B
rsi-technicals
43.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBT VS. FCX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBT | FCX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | 26.10% | -0.80 | FCX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.30% | 21.50% | +0.80 | CBT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.2x | 13.4x | -8.20 | CBT | /valuation <GO> |
| Free Cash Flow Yield | 10.25% | 4.71% | +5.54 | CBT | /fcf-yield <GO> |
| Operating Margin | 16.70% | 25.90% | -9.20 | FCX | /operating-margins <GO> |
| Net Profit Margin | 8.90% | 8.80% | +0.10 | CBT | /net-margins <GO> |
| Revenue Growth (YoY) | -7.00% | 0.10% | -7.10 | FCX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.52% | 0.91% | +1.61 | CBT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.08 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 40.6 | 43.5 | -2.90 | FCX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.95 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 40.1x | -29.40 | CBT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.81B | $94.98B | -$91.17B | FCX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBT REV | FCX REV | CBT GROSS % | FCX GROSS % | CBT FCF | FCX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $25.19B | 25.3% | 26.1% | $391.0M | $4.48B |
| FY 2024 | $3.99B | $25.17B | 24.0% | 29.3% | $451.0M | $6.03B |
| FY 2023 | $3.93B | $22.70B | — | — | $595.0M | $4.26B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBT // BETA —
FCX // BETA 0.95